{"protocolSection":{"identificationModule":{"nctId":"NCT01652729","orgStudyIdInfo":{"id":"BCB120"},"secondaryIdInfos":[{"id":"MB001-004","type":"OTHER","domain":"Bristol Myers Squibb"}],"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus","officialTitle":"A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus","acronym":"DURATION-NEO-2"},"statusModule":{"statusVerifiedDate":"2015-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-02"},"primaryCompletionDateStruct":{"date":"2014-04","type":"ACTUAL"},"completionDateStruct":{"date":"2014-04","type":"ACTUAL"},"studyFirstSubmitDate":"2012-07-26","studyFirstSubmitQcDate":"2012-07-27","studyFirstPostDateStruct":{"date":"2012-07-30","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-04-03","resultsFirstSubmitQcDate":"2015-04-08","resultsFirstPostDateStruct":{"date":"2015-04-23","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-07-31","lastUpdatePostDateStruct":{"date":"2015-08-20","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by sitagliptin or placebo administered once daily for 28 weeks in subjects with type 2 diabetes mellitus."},"conditionsModule":{"conditions":["Diabetes Type 2"],"keywords":["Diabetes, Type 2, exenatide, Sitagliptin"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":365,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Exenatide once weekly suspension","type":"EXPERIMENTAL","description":"Exenatide once weekly suspension 2mg subcutaneous injection","interventionNames":["Drug: Exenatide once weekly suspension"]},{"label":"Sitagliptin 100mg","type":"ACTIVE_COMPARATOR","description":"Overencapsulated Sitagliptin 100mg oral tablet once daily","interventionNames":["Drug: Sitagliptin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo oral capsule once daily","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Exenatide once weekly suspension","armGroupLabels":["Exenatide once weekly suspension"]},{"type":"DRUG","name":"Sitagliptin","armGroupLabels":["Sitagliptin 100mg"]},{"type":"DRUG","name":"Placebo","description":"Placebo oral capsule once daily","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28","description":"Absolute change in HbA1c from baseline (Day 1, Visit 3) to Week 28/Study Termination (Visit 11). Hypothesis testing on the primary endpoint followed a serial gated procedure with all tests carried out at a 2-sided significance level of 0.05 to protect the family-wise error rate. These tests were conducted sequentially, and are presented in the statistical analysis section below in the order in which they were performed; each test was the gatekeeper of later tests.","timeFrame":"Baseline to Week 28"}],"secondaryOutcomes":[{"measure":"Percentage of Subjects Achieving HbA1c <7% at Week 28","description":"Percentage of subjects achieving HbA1c target values of \\< 7.0% at Week 28/Study Termination.","timeFrame":"Baseline to Week 28"},{"measure":"Change in Fasting Plasma Glucose Concentrations From Baseline to Week 28","description":"The change in fasting plasma glucose concentrations from baseline (Day 1) to Week 28/Study Termination.","timeFrame":"Baseline to Week 28"},{"measure":"Change in Body Weight (kg) From Baseline to Week 28","description":"The change in body weight (kg) from baseline (Day 1) to Week 28/Study Termination.","timeFrame":"Baseline to Week 28"},{"measure":"Change in 2-hour Postprandial Glucose Concentrations From Baseline to Week 16 (Visit 8)","description":"The change in 2-hour postprandial plasma glucose from baseline (Day 1) to Visit 8 (Week 16) was analyzed using a general linear model including treatment, and baseline HbA1c stratum (\\< 9% or ≥ 9%) as fixed factors, and the baseline 2-hour postprandial plasma glucose concentrations as a covariate.","timeFrame":"Baseline to Week 16"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years old\n* Diagnosed with type 2 diabetes mellitus\n* HbA1c of 7.1% to 11.0%, inclusive, at screening\n* Has stable body weight, i.e., not varying by \\>3% for at least 3 months prior to screening\n* Fasting plasma glucose concentration \\<280 mg/dL (15.5 mmol/L) at screening\n* Body mass index of \\<45 kg/m2 at screening\n* Has been treated with a stable regimen of ≥1500 mg/day metformin for a minimum of 2 months prior to Visit 1 (Screening)\n\nExclusion Criteria:\n\n* History of pancreatitis or triglycerides \\>=500 mg/dL\n* Medullary carcinoma or multiple endocrine neoplasia (MEN2) or a family history of either\n* History of renal transplantation, or is currently receiving renal dialysis, or has an estimated creatinine clearance \\<50 mL/min\n* Active cardiovascular disease\n* Presence or history of severe congestive heart failure\n* Central nervous system disease, including epilepsy\n* Liver disease\n* History of severe gastrointestinal diseases\n* Clinically significant malignant disease\n* Repeated severe hypoglycemia within the last 6 months\n* Any exposure to exenatide (BYETTA® or BYDUREON™) or any GLP-1 analog\n* Any DPP-4 inhibitor within 3 months prior screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Peter Ohman","affiliation":"AstraZeneca","role":"STUDY_CHAIR"}],"locations":[{"facility":"Research Site","city":"Birmingham","state":"Alabama","zip":"35216","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Research Site","city":"Huntsville","state":"Alabama","zip":"35801","country":"United States","geoPoint":{"lat":34.7304,"lon":-86.58594}},{"facility":"Research Site","city":"Phoenix","state":"Arizona","zip":"85018","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Research Site","city":"Phoenix","state":"Arizona","zip":"85020","country":"United States","geoPoint":{"lat":33.44838,"lon":-112.07404}},{"facility":"Research Site","city":"Beverly Hills","state":"California","zip":"90036","country":"United States","geoPoint":{"lat":34.07362,"lon":-118.40036}},{"facility":"Research Site","city":"Buena Park","state":"California","zip":"90620","country":"United States","geoPoint":{"lat":33.86751,"lon":-117.99812}},{"facility":"Research Site","city":"Chino","state":"California","zip":"91710","country":"United States","geoPoint":{"lat":34.01223,"lon":-117.68894}},{"facility":"Research Site","city":"Chula Vista","state":"California","zip":"91910","country":"United States","geoPoint":{"lat":32.64005,"lon":-117.0842}},{"facility":"Research Site","city":"Encinitas","state":"California","zip":"92024","country":"United States","geoPoint":{"lat":33.03699,"lon":-117.29198}},{"facility":"Research Site","city":"Greenbrae","state":"California","zip":"94904","country":"United States","geoPoint":{"lat":37.94854,"lon":-122.5247}},{"facility":"Research Site","city":"Los Angeles","state":"California","zip":"90057","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Research Site","city":"Los Angeles","state":"California","zip":"90059","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Research Site","city":"North Hollywood","state":"California","zip":"91606","country":"United States","geoPoint":{"lat":34.17223,"lon":-118.37897}},{"facility":"Research Site","city":"Walnut Creek","state":"California","zip":"94598","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"facility":"Research Site","city":"West Hills","state":"California","zip":"91307","country":"United States","geoPoint":{"lat":34.19731,"lon":-118.64398}},{"facility":"Research Site","city":"Boca Raton","state":"Florida","zip":"33432","country":"United States","geoPoint":{"lat":26.35869,"lon":-80.0831}},{"facility":"Research Site","city":"Hialeah","state":"Florida","zip":"33012","country":"United States","geoPoint":{"lat":25.8576,"lon":-80.27811}},{"facility":"Research Site","city":"Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Research Site","city":"Miami","state":"Florida","zip":"33169","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Research Site","city":"Miami","state":"Florida","zip":"33183","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Research Site","city":"Port Orange","state":"Florida","zip":"32127","country":"United States","geoPoint":{"lat":29.13832,"lon":-80.99561}},{"facility":"Research Site","city":"St. Petersburg","state":"Florida","zip":"33709","country":"United States","geoPoint":{"lat":27.77086,"lon":-82.67927}},{"facility":"Research Site","city":"Chicago","state":"Illinois","zip":"60607","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"Research Site","city":"Evanston","state":"Illinois","zip":"60201","country":"United States","geoPoint":{"lat":42.04114,"lon":-87.69006}},{"facility":"Research Site","city":"Indianapolis","state":"Indiana","zip":"46254","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"Research Site","city":"Oxon Hill","state":"Maryland","zip":"20745","country":"United States","geoPoint":{"lat":38.80345,"lon":-76.9897}},{"facility":"Research Site","city":"Omaha","state":"Nebraska","zip":"68130","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Research Site","city":"Henderson","state":"Nevada","zip":"89052","country":"United States","geoPoint":{"lat":36.0397,"lon":-114.98194}},{"facility":"Research Site","city":"Las Vegas","state":"Nevada","zip":"89101","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Research Site","city":"Las Vegas","state":"Nevada","zip":"89123","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Research Site","city":"Albuquerque","state":"New Mexico","zip":"87102","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"Research Site","city":"Buffalo","state":"New York","zip":"14215","country":"United States","geoPoint":{"lat":42.88645,"lon":-78.87837}},{"facility":"Research Site","city":"Hartsdale","state":"New York","zip":"10530","country":"United States","geoPoint":{"lat":41.01899,"lon":-73.79819}},{"facility":"Research Site","city":"Charlotte","state":"North Carolina","zip":"28204","country":"United States","geoPoint":{"lat":35.22709,"lon":-80.84313}},{"facility":"Research Site","city":"Clayton","state":"North Carolina","zip":"27520","country":"United States","geoPoint":{"lat":35.65071,"lon":-78.45639}},{"facility":"Research Site","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Research Site","city":"Greensboro","state":"North Carolina","zip":"27410","country":"United States","geoPoint":{"lat":36.07264,"lon":-79.79198}},{"facility":"Research Site","city":"Mooresville","state":"North Carolina","zip":"28117","country":"United States","geoPoint":{"lat":35.58486,"lon":-80.81007}},{"facility":"Research Site","city":"Salisbury","state":"North Carolina","zip":"28144","country":"United States","geoPoint":{"lat":35.67097,"lon":-80.47423}},{"facility":"Research Site","city":"Cincinnati","state":"Ohio","zip":"45246","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Research Site","city":"Franklin","state":"Ohio","zip":"45005","country":"United States","geoPoint":{"lat":39.55895,"lon":-84.30411}},{"facility":"Research Site","city":"Marion","state":"Ohio","zip":"43302","country":"United States","geoPoint":{"lat":40.58867,"lon":-83.12852}},{"facility":"Research Site","city":"Yukon","state":"Oklahoma","zip":"73099","country":"United States","geoPoint":{"lat":35.50672,"lon":-97.76254}},{"facility":"Research Site","city":"Eugene","state":"Oregon","zip":"97404","country":"United States","geoPoint":{"lat":44.05207,"lon":-123.08675}},{"facility":"Research Site","city":"Portland","state":"Oregon","zip":"97210","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Research Site","city":"Greer","state":"South Carolina","zip":"29651","country":"United States","geoPoint":{"lat":34.93873,"lon":-82.22706}},{"facility":"Research Site","city":"Simpsonville","state":"South Carolina","zip":"29681","country":"United States","geoPoint":{"lat":34.73706,"lon":-82.25428}},{"facility":"Reseach Site","city":"Rapid City","state":"South Dakota","zip":"57702","country":"United States","geoPoint":{"lat":44.08054,"lon":-103.23101}},{"facility":"Research Site","city":"Chattanooga","state":"Tennessee","zip":"37421","country":"United States","geoPoint":{"lat":35.04563,"lon":-85.30968}},{"facility":"Research Site","city":"Carrolton","state":"Texas","zip":"75007","country":"United States"},{"facility":"Research Site","city":"Corpus Christi","state":"Texas","zip":"78404","country":"United States","geoPoint":{"lat":27.80058,"lon":-97.39638}},{"facility":"Research Site","city":"Dallas","state":"Texas","zip":"75390","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Research Site","city":"Houston","state":"Texas","zip":"77072","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Research Site","city":"Houston","state":"Texas","zip":"77074","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Research Site","city":"Katy","state":"Texas","zip":"77450","country":"United States","geoPoint":{"lat":29.78579,"lon":-95.8244}},{"facility":"Research Site","city":"San Antonio","state":"Texas","zip":"78205","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Research Site","city":"Salt Lake City","state":"Utah","zip":"84095","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Research Site","city":"Salt Lake City","state":"Utah","zip":"84107","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Research Site","city":"Burke","state":"Virginia","zip":"22015","country":"United States","geoPoint":{"lat":38.79345,"lon":-77.27165}},{"facility":"Research Site","city":"Spokane","state":"Washington","zip":"99202","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}}]},"referencesModule":{"references":[{"pmid":"32306296","type":"DERIVED","citation":"Guja C, Frias JP, Suchower L, Hardy E, Marr G, Sjostrom CD, Jabbour SA. Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease. Diabetes Ther. 2020 Jul;11(7):1467-1480. doi: 10.1007/s13300-020-00815-z. Epub 2020 Apr 18."},{"pmid":"28205322","type":"DERIVED","citation":"Gadde KM, Vetter ML, Iqbal N, Hardy E, Ohman P; DURATION-NEO-2 study investigators. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study. Diabetes Obes Metab. 2017 Jul;19(7):979-988. doi: 10.1111/dom.12908. Epub 2017 Mar 17."}],"seeAlsoLinks":[{"label":"BCB120\\_Synopsis","url":"http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=2733&filename=BCB120_Synopsis.pdf"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Subjects were randomly assigned across 3 treatment groups (exenatide, sitagliptin, and placebo) in a ratio of 3:2:1, with randomization stratified by screening HbA1c stratum (\\< 9% or 9%).","groups":[{"id":"FG000","title":"Experimental: Exenatide","description":"Exenatide once weekly suspension 2mg subcutaneous injection"},{"id":"FG001","title":"Active Comparator: Sitagliptin","description":"Sitagliptin 100mg oral tablet once daily"},{"id":"FG002","title":"Placebo Comparator: Placebo","description":"Placebo oral tablet once daily"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"One subject was enrolled twice at different sites. He was randomized to exenatide at both sites.","numSubjects":"182"},{"groupId":"FG001","numSubjects":"122"},{"groupId":"FG002","numSubjects":"61"}]},{"type":"Modified Intent-to-Treat","achievements":[{"groupId":"FG000","comment":"All randomized subjects who received at least one dose of study drug.","numSubjects":"181"},{"groupId":"FG001","numSubjects":"122"},{"groupId":"FG002","numSubjects":"61"}]},{"type":"Treated","achievements":[{"groupId":"FG000","comment":"All subjects who received at least one dose of study medication even if not randomized.","numSubjects":"181"},{"groupId":"FG001","numSubjects":"122"},{"groupId":"FG002","numSubjects":"61"}]},{"type":"Evaluable","achievements":[{"groupId":"FG000","comment":"Subjects who completed study procedures to Week 24 or beyond and had adequate study drug exposure","numSubjects":"143"},{"groupId":"FG001","numSubjects":"91"},{"groupId":"FG002","numSubjects":"43"}]},{"type":"Meal Test Subjects","achievements":[{"groupId":"FG000","numSubjects":"60"},{"groupId":"FG001","numSubjects":"41"},{"groupId":"FG002","numSubjects":"20"}]},{"type":"Meal Test Evaluable","achievements":[{"groupId":"FG000","comment":"ITT subjects who ate \\>=75% of meal and did not miss 2-hour postprandial glucose measures at V3 and 8","numSubjects":"44"},{"groupId":"FG001","numSubjects":"31"},{"groupId":"FG002","numSubjects":"15"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"The double-enrolled subject's reasons for withdrawal were LTFU and PV. Only PV is shown below.","numSubjects":"155"},{"groupId":"FG001","numSubjects":"109"},{"groupId":"FG002","numSubjects":"47"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"14"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"7"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Administrative","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Modified Intent-to-Treat: Subjects who were randomized and received at least one dose of study drug.","groups":[{"id":"BG000","title":"Experimental: Exenatide","description":"Exenatide once weekly suspension 2mg subcutaneous injection"},{"id":"BG001","title":"Active Comparator: Sitagliptin","description":"Sitagliptin 100mg oral tablet once daily"},{"id":"BG002","title":"Placebo Comparator: Placebo","description":"Placebo oral tablet once daily"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"181"},{"groupId":"BG001","value":"122"},{"groupId":"BG002","value":"61"},{"groupId":"BG003","value":"364"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"53.4","spread":"9.82"},{"groupId":"BG001","value":"54.3","spread":"9.01"},{"groupId":"BG002","value":"53.4","spread":"9.48"},{"groupId":"BG003","value":"53.7","spread":"9.49"}]}]}]},{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"<65 years","categories":[{"measurements":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"106"},{"groupId":"BG002","value":"54"},{"groupId":"BG003","value":"314"}]}]},{"title":">=65 years","categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"50"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"92"},{"groupId":"BG001","value":"56"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"172"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"89"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"37"},{"groupId":"BG003","value":"192"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"98"},{"groupId":"BG002","value":"50"},{"groupId":"BG003","value":"296"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"49"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"14"}]}]},{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"111"},{"groupId":"BG001","value":"77"},{"groupId":"BG002","value":"32"},{"groupId":"BG003","value":"220"}]}]},{"title":"Not Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"29"},{"groupId":"BG003","value":"144"}]}]}]},{"title":"Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"89.15","spread":"21.413"},{"groupId":"BG001","value":"88.09","spread":"20.282"},{"groupId":"BG002","value":"88.95","spread":"20.136"},{"groupId":"BG003","value":"88.76","spread":"20.778"}]}]}]},{"title":"Baseline HbA1c","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"percentage of total hemoglobin","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.42","spread":"0.997"},{"groupId":"BG001","value":"8.50","spread":"1.043"},{"groupId":"BG002","value":"8.50","spread":"1.043"},{"groupId":"BG003","value":"8.46","spread":"1.018"}]}]}]},{"title":"HbA1c Stratum","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"< 9.0%","categories":[{"measurements":[{"groupId":"BG000","value":"125"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"42"},{"groupId":"BG003","value":"250"}]}]},{"title":">= 9.0%","categories":[{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"114"}]}]}]},{"title":"Fasting Plasma Glucose","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"mg/dL","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"178.0","spread":"46.64"},{"groupId":"BG001","value":"176.9","spread":"42.50"},{"groupId":"BG002","value":"172.8","spread":"44.31"},{"groupId":"BG003","value":"176.8","spread":"44.82"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28","description":"Absolute change in HbA1c from baseline (Day 1, Visit 3) to Week 28/Study Termination (Visit 11). Hypothesis testing on the primary endpoint followed a serial gated procedure with all tests carried out at a 2-sided significance level of 0.05 to protect the family-wise error rate. These tests were conducted sequentially, and are presented in the statistical analysis section below in the order in which they were performed; each test was the gatekeeper of later tests.","populationDescription":"Modified Intent-to-Treat: Subjects who were randomized and received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"percentage of total hemoglobin","timeFrame":"Baseline to Week 28","groups":[{"id":"OG000","title":"Experimental: Exenatide","description":"Exenatide once weekly suspension 2mg subcutaneous injection"},{"id":"OG001","title":"Active Comparator: Sitagliptin","description":"Sitagliptin 100mg oral tablet once daily"},{"id":"OG002","title":"Placebo Comparator: Placebo","description":"Placebo oral tablet once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"122"},{"groupId":"OG002","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.13","spread":"0.1093"},{"groupId":"OG001","value":"-0.75","spread":"0.1324"},{"groupId":"OG002","value":"-0.40","spread":"0.1945"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0010","statisticalMethod":"mixed model for repeated measure","statisticalComment":"MMRM includes treatment, baseline HbA1c (\\<9% or ≥9%), week of visit and treatment by visit interaction as fixed factors, and subject random effect.","paramType":"LS Mean Difference","paramValue":"-0.72","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.15","ciUpperLimit":"-0.30","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.2167"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0209","statisticalMethod":"mixed model for repeated measure","statisticalComment":"MMRM includes treatment, baseline HbA1c (\\<9% or ≥9%), week of visit and treatment by visit interaction as fixed factors, and subject random effect.","paramType":"LS Mean Difference","paramValue":"-0.38","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.70","ciUpperLimit":"-0.06","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.1638"},{"groupIds":["OG001","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1347","statisticalMethod":"mixed model for repeated measure","statisticalComment":"MMRM includes treatment, baseline HbA1c (\\<9% or ≥9%), week of visit and treatment by visit interaction as fixed factors, and subject random effect.","paramType":"LS Mean Difference","paramValue":"-0.34","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.79","ciUpperLimit":"0.11","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.2278"}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving HbA1c <7% at Week 28","description":"Percentage of subjects achieving HbA1c target values of \\< 7.0% at Week 28/Study Termination.","populationDescription":"Modified Intent-to-Treat: Subjects who were randomized and received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of subjects","timeFrame":"Baseline to Week 28","groups":[{"id":"OG000","title":"Experimental: Exenatide","description":"Exenatide once weekly suspension 2mg subcutaneous injection"},{"id":"OG001","title":"Active Comparator: Sitagliptin","description":"Sitagliptin 100mg oral tablet once daily"},{"id":"OG002","title":"Placebo Comparator: Placebo","description":"Placebo oral tablet once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"122"},{"groupId":"OG002","value":"61"}]}],"classes":[{"title":"Baseline Yes","categories":[{"measurements":[{"groupId":"OG000","value":"3.3"},{"groupId":"OG001","value":"1.6"},{"groupId":"OG002","value":"3.3"}]}]},{"title":"Baseline No","categories":[{"measurements":[{"groupId":"OG000","value":"96.7"},{"groupId":"OG001","value":"98.4"},{"groupId":"OG002","value":"96.7"}]}]},{"title":"Week 28 Yes","categories":[{"measurements":[{"groupId":"OG000","value":"43.1"},{"groupId":"OG001","value":"32.0"},{"groupId":"OG002","value":"24.6"}]}]},{"title":"Week 28 No","categories":[{"measurements":[{"groupId":"OG000","value":"56.9"},{"groupId":"OG001","value":"68.0"},{"groupId":"OG002","value":"75.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Percentage of Subjects Achieving HbA1c \\<7% at Week 28.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0489","statisticalMethod":"Cochran-Mantel-Haenszel"},{"groupIds":["OG000","OG002"],"groupDescription":"Percentage of Subjects Achieving HbA1c \\<7% at Week 28.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0103","statisticalMethod":"Cochran-Mantel-Haenszel"}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose Concentrations From Baseline to Week 28","description":"The change in fasting plasma glucose concentrations from baseline (Day 1) to Week 28/Study Termination.","populationDescription":"Modified Intent-to-Treat: Subjects who were randomized and received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Baseline to Week 28","groups":[{"id":"OG000","title":"Experimental: Exenatide","description":"Exenatide once weekly suspension 2mg subcutaneous injection"},{"id":"OG001","title":"Active Comparator: Sitagliptin","description":"Sitagliptin 100mg oral tablet once daily"},{"id":"OG002","title":"Placebo Comparator: Placebo","description":"Placebo oral tablet once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"122"},{"groupId":"OG002","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.3","spread":"3.864"},{"groupId":"OG001","value":"-11.3","spread":"4.617"},{"groupId":"OG002","value":"9.6","spread":"7.097"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0924","statisticalMethod":"mixed model for repeated measure","statisticalComment":"MMRM includes treatment, baseline HbA1c (\\<9% or ≥9%), week of visit and treatment by visit interaction as fixed factors, and subject random effect.","paramType":"LS Mean Difference","paramValue":"-10.1","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-21.8","ciUpperLimit":"1.7","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"5.960"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0001","statisticalMethod":"mixed model for repeated measure","statisticalComment":"MMRM includes treatment, baseline HbA1c (\\<9% or ≥9%), week of visit and treatment by visit interaction as fixed factors, and subject random effect.","paramType":"LS Mean Difference","paramValue":"-30.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-46.7","ciUpperLimit":"-15.1","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"8.037"}]},{"type":"SECONDARY","title":"Change in Body Weight (kg) From Baseline to Week 28","description":"The change in body weight (kg) from baseline (Day 1) to Week 28/Study Termination.","populationDescription":"Modified Intent-to-Treat: Subjects who were randomized and received at least one dose of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kg","timeFrame":"Baseline to Week 28","groups":[{"id":"OG000","title":"Experimental: Exenatide","description":"Exenatide once weekly suspension 2mg subcutaneous injection"},{"id":"OG001","title":"Active Comparator: Sitagliptin","description":"Sitagliptin 100mg oral tablet once daily"},{"id":"OG002","title":"Placebo Comparator: Placebo","description":"Placebo oral tablet once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"122"},{"groupId":"OG002","value":"61"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.12","spread":"0.2592"},{"groupId":"OG001","value":"-1.19","spread":"0.3134"},{"groupId":"OG002","value":"0.15","spread":"0.4767"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8625","pValueComment":"Nominal p-value","statisticalMethod":"mixed model for repeated measure","statisticalComment":"MMRM includes treatment, baseline HbA1c (\\<9% or ≥9%), week of visit and treatment by visit interaction as fixed factors, and subject random effect.","paramType":"LS Mean Difference","paramValue":"0.07","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.73","ciUpperLimit":"0.87","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.4058"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0198","pValueComment":"Nominal p-value","statisticalMethod":"mixed model for repeated measure","statisticalComment":"MMRM includes treatment, baseline HbA1c (\\<9% or ≥9%), week of visit and treatment by visit interaction as fixed factors, and subject random effect.","paramType":"LS Mean Difference","paramValue":"-1.27","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.34","ciUpperLimit":"-0.20","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.5419"}]},{"type":"SECONDARY","title":"Change in 2-hour Postprandial Glucose Concentrations From Baseline to Week 16 (Visit 8)","description":"The change in 2-hour postprandial plasma glucose from baseline (Day 1) to Visit 8 (Week 16) was analyzed using a general linear model including treatment, and baseline HbA1c stratum (\\< 9% or ≥ 9%) as fixed factors, and the baseline 2-hour postprandial plasma glucose concentrations as a covariate.","populationDescription":"Meal Test Evaluable Population: The Meal Test Evaluable Population consists of all modified ITT subjects who participated in the meal test, consumed at least 75% of the standardized meal and had no missing 2-hour postprandial glucose measurements at both Visit 3 (Day 1) and Visit 8 (Week 16), and have adequate study drug exposure.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Baseline to Week 16","groups":[{"id":"OG000","title":"Experimental: Exenatide","description":"Exenatide once weekly suspension 2mg subcutaneous injection"},{"id":"OG001","title":"Active Comparator: Sitagliptin","description":"Sitagliptin 100mg oral tablet once daily"},{"id":"OG002","title":"Placebo Comparator: Placebo","description":"Placebo oral tablet once daily"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.57","spread":"10.48"},{"groupId":"OG001","value":"-23.61","spread":"13.04"},{"groupId":"OG002","value":"-38.68","spread":"16.98"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0248","pValueComment":"Nominal p-value","statisticalMethod":"general linear model","statisticalComment":"Includes treatment and baseline HbA1c (\\< 9% or ≥ 9%) as fixed factors, and baseline 2-hour postprandial plasma glucose concentrations as a covariate.","paramType":"LS Mean Difference","paramValue":"-35.96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-67.23","ciUpperLimit":"-4.68","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"15.71"},{"groupIds":["OG000","OG002"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2914","pValueComment":"Nominal p-value","statisticalMethod":"general linear model","statisticalComment":"Includes treatment and baseline HbA1c (\\< 9% or ≥ 9%) as fixed factors, and baseline 2-hour postprandial plasma glucose concentrations as a covariate.","paramType":"LS Mean Difference","paramValue":"-20.89","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-60.02","ciUpperLimit":"18.25","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"19.66"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Experimental: Exenatide","description":"Exenatide once weekly suspension 2mg subcutaneous injection","seriousNumAffected":5,"seriousNumAtRisk":181,"otherNumAffected":31,"otherNumAtRisk":181},{"id":"EG001","title":"Active Comparator: Sitagliptin","description":"Sitagliptin 100mg oral tablet once daily","seriousNumAffected":0,"seriousNumAtRisk":122,"otherNumAffected":2,"otherNumAtRisk":122},{"id":"EG002","title":"Placebo Comparator: Placebo","description":"Placebo oral tablet once daily","seriousNumAffected":2,"seriousNumAtRisk":61,"otherNumAffected":4,"otherNumAtRisk":61}],"seriousEvents":[{"term":"Abdominal Hernia Obstructive","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":122},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":122},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Rheumatoid Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":122},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Breast Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":122},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Brain Stem Infarction","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":122},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Acute Myocardial Infarction","organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":122},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Coronary Artery Disease","organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":122},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":181},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":122},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":61}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numEvents":18,"numAffected":16,"numAtRisk":181},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":122},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Injection Site Nodule","organSystem":"General disorders","stats":[{"groupId":"EG000","numEvents":19,"numAffected":14,"numAtRisk":181},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":122},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":61}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":181},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":122},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":61}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"LTE60","restrictiveAgreement":true},"pointOfContact":{"title":"ClinicalTrialTransparency@astrazeneca.com","organization":"AstraZeneca","email":"ClinicalTrialTransparency@astrazeneca.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"},{"id":"D003920","term":"Diabetes Mellitus"}],"ancestors":[{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068900","term":"Sitagliptin Phosphate"}],"ancestors":[{"id":"D014230","term":"Triazoles"},{"id":"D001393","term":"Azoles"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D011719","term":"Pyrazines"}]}},"hasResults":true}